Our findings encourage further investigation into the development of therapeutic strategies for feline mast cell tumours, particularly focusing on the heterogeneous nature of KIT/KIT and overcoming acquired resistance to toceranib. This evidence concerns the gene KIT and mast cell neoplasm.